Post-COVID-19 Intestinal and Mesenteric Mucormycosis

Banerjee, Niladri; Lodha, Mahendra; Baskaran, Suruthi; Chawla, Siddhi

doi:10.1177/00031348211048841

Cited by 2 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conditions like hemochromatosis and the use of iron chelators such as deferoxamine elevate the risk of mucormycosis. Our patient had poorly controlled blood sugar levels, and was pretreated with corticosteroids before manifesting symptoms of cutaneous mucormycosis [7]. As reported by Song G et al, severely ill COVID-19 patients who require prolonged hospitalization, admission to the intensive care unit (ICU), or invasive mechanical ventilation are particularly vulnerable to invasive mycoses [16].…”

Section: Discussionmentioning

confidence: 61%

“…There is evidence of a rising number of cases among patients who have successfully recovered from initial COVID-19 infection, with the vast majority originating in the subcontinent region [6]. Patients may have an increased susceptibility to CAM due to their compromised immune status, which can result from the viral infection itself, previous corticosteroid therapy, or uncontrolled blood sugar levels [7]. Studies have indicated that the median duration for the development of mucormycosis is approximately 10 to 15 days following a COVID-19 diagnosis [8].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

COVID-19 Associated Mucormycosis and Cytomegalovirus Infection – A Case Report

Khan,

Zaina,

Parvez

et al. 2023

Preprint

View full text Add to dashboard Cite

Mucormycosis is an opportunistic fungal infection that is increasingly affecting patients with Coronavirus Disease (COVID-19). This connection is particularly pronounced in specific populations, including individuals with diabetes or those who have recently undergone corticosteroid therapy. Additionally, Cytomegalovirus (CMV) infection is a frequent complication among COVID-19 patients who have previously received corticosteroid or other immune-modulatory treatments. In this case report, we present the clinical details of a 56-year-old male who developed post-COVID pneumonia complicated by both cutaneous mucormycosis and CMV infection.

show abstract

Section: Discussionmentioning

confidence: 61%

Section: Introductionmentioning

confidence: 99%

COVID-19 Associated Mucormycosis and Cytomegalovirus Infection – A Case Report

Khan,

Zaina,

Parvez

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

Intestinal ischemia in COVID-19 patients: A case series

et al. 2023

View full text Add to dashboard Cite

Introduction: COVID-19 is associated with increased coagulability, resulting in thromboembolic complications, such as intestinal ischemia. Diagnosis of bowel infarction can be challenging due to the severity of illness and the laboratory changes associated with the COVID-19 infection itself. Case Series: In a retrospective monocentric study, we performed an in-depth analysis of the clinical course of intestinal ischemia in COVID-19 patients. Biochemical analysis of coagulation status and predictors of ischemia was performed. We identified five patients with intestinal ischemia, between March 2020 and January 2021. Mean time-to-onset of intestinal ischemia from COVID-diagnosis was 31 days (range 16–56). Intestinal ischemia was confirmed by contrast-enhanced computed tomography (CT) scan. D-dimer, Fibrinogen, C-reactive protein (CRP), and lactate dehydrogenase (LDH) were elevated prior to the ischemic event, but no recurrent pattern could be distinguished in our case series. Lactate levels demonstrated a marked increase at the time of ischemia in our series. No consistent findings were made for prothrombin time (PT) and activated partial thromboplastin time (aPTT) and creatin kinase. Extent of bowel ischemia varied between limited to the ileocecal region (two patients), additional ischemia of small and large bowel (two patients) and extensive ischemia of entire intestinal tract (one patient). Four patients (80%) required an ileostomy. Planned relook surgery was performed in three patients (60%). Three (60%) patients died. Conclusion: In the five days prior to an intestinal ischemic event in COVID-19 patients, we did not identify a clear pattern in commonly used markers for coagulation status and ischemia. However, lactate levels showed a recurrent pattern of clear increase leading up to the ischemic event and rapid normalization after surgery. Unfortunately, our patient numbers were too small to draw definitive conclusions.

show abstract

Post-COVID-19 Intestinal and Mesenteric Mucormycosis

Cited by 2 publications

References 4 publications

COVID-19 Associated Mucormycosis and Cytomegalovirus Infection – A Case Report

COVID-19 Associated Mucormycosis and Cytomegalovirus Infection – A Case Report

Intestinal ischemia in COVID-19 patients: A case series

Contact Info

Product

Resources

About